

On page 16, line 2, correct "by" to read: --be--.

On page 22, line 27, insert after "glu-ala-ala-glu" the following: --(SEQ ID NO. 70)--.

Delete the previously submitted Sequence Listing, pages 44-68, and substitute the replacement Sequence Listing provided herewith in its place. The replacement Sequence Listing is on pages numbered from 44 through 81. Please renumber the pages following the Sequence Listing appropriately.

Insert, on a separate page at the end of the application, the following Abstract:

--Abstract of the Disclosure

*B2*  
Proteins are disclosed that are homologous to bovine pancreatic trypsin inhibitor (BPTI) Kunitz domains, and especially proteins that are homologous to lipoprotein-associated coagulation inhibitor (LACI) Kunitz domains, which inhibit one or more plasma and/or tissue kallikreins, and uses of such proteins in therapeutic and diagnostic methods also are disclosed. In particular, Kunitz domains derived from Kunitz domains of human origin and especially to the first Kunitz domain of LACI are disclosed...

A separate sheet containing the foregoing Abstract is also transmitted herewith.

IN THE CLAIMS

Please amend claims 4, 6, 7, 9, 10, 12 and 13 under the provisions of 37 CFR §1.121(b) as follows:

*C 10*  
(amended) A plasma kallikrein inhibiting protein which comprises a sequence that is substantially homologous to a reference sequence being selected from the group consisting of: KKII/3 #1 (SEQ ID NO. 5), KKII/3 #2 (SEQ ID NO. 6), KKII/3 #3 (SEQ ID NO. 7), KKII/3 #4 (SEQ ID NO. 8), KKII/3 #5 (SEQ ID NO. 9), KKII/3 #6 (SEQ ID NO. 10), KKII/3 #7 (SEQ ID NO. 11), KKII/3 #8 (SEQ ID NO. 12), KKII/3 #9 (SEQ ID NO. 13), KKII/3 #10 (SEQ ID NO. 15), KK2/ #11 (SEQ ID NO. 22), KK2/ #13 (SEQ ID NO. 19), KK2/ #1 (SEQ ID NO. 23), [KK2/ #2], KK2/ #3 (SEQ ID NO. 28), KK2/ #4 (SEQ ID NO. 24), KK2/ #6 (SEQ ID NO. 25), KK2/ #7 (SEQ ID NO. 30), KK2/ #8 (SEQ ID NO. 27), KK2/ #9 (SEQ ID NO. 29), KK2/ #10 (SEQ ID NO. 27), KK2/ #12 (SEQ ID NO. 31), and [AND] KK2con1 (SEQ ID NO. 32) as defined in Table 2.

*B3*  
6: (twice amended) A method of assaying for the presence of kallikrein in a sample which method comprises: providing the protein of claim 1 in labeled or insolubilized form,

*68*